Immix Biopharma, Inc.
A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.
About
Immix Biopharma is a biopharmaceutical company developing a revolutionary one-time CAR-T therapy, NXC-201, designed to re-engineer the immune system to fight AL Amyloidosis. This therapy targets diseased cells, aiming to normalize disease within days and provide a durable response with minimal side effects, particularly for vulnerable patients with heart involvement. Immix Biopharma is focused on creating medicines that are both effective and safe, addressing the critical unmet need for relapsed/refractory AL amyloidosis patients. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Immix Biopharma, Inc. do?
Immix Biopharma, Inc. is a Biotechnology company that offers Platform. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in Los Angeles, United States. Public records show about 53 people and $5M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Immix Biopharma, Inc. raised?
Immix Biopharma, Inc. has raised a total of $5M in funding. The most recent round on record is At-The-Market Equity Offering.
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. is headquartered in Los Angeles, United States.
What industry does Immix Biopharma, Inc. operate in?
Immix Biopharma, Inc. operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, MedTech.
How many employees does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has approximately 53 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
